(Q38103912)

English

Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials

scientific article published on 04 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

author name string

Yoshiki Higashijima

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Tetsuhiro Tanaka

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Masaomi Nangaku

3

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

language of work or name

0 references

publication date

4 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Expert Opinion on Drug Discovery

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

965-976

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Anemia of chronic disease.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Erythropoiesis-stimulating agents: past and future

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Mechanisms of anemia in CKD.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Repression via the GATA box is essential for tissue-specific erythropoietin gene expression.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Isolation and characterization of genomic and cDNA clones of human erythropoietin

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Cloning and expression of the human erythropoietin gene

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

A gain-of-function mutation in the HIF2A gene in familial erythrocytosis

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

The length of peptide substrates has a marked effect on hydroxylation by the hypoxia-inducible factor prolyl 4-hydroxylases

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production and erythropoiesis

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Mammalian EGLN genes have distinct patterns of mRNA expression and regulation

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Iron sensing and signalling

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

HIF prolyl hydroxylase inhibitors for anemia

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs).

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Regulation of the HIF-1alpha level is essential for hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Stem cell quiescence

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Pharmacologic stabilization of HIF-1α increases hematopoietic stem cell quiescence in vivo and accelerates blood recovery after severe irradiation.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Structure-based drug design strategies in medicinal chemistry

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Drug repositioning: identifying and developing new uses for existing drugs

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Drug discovery in pharmaceutical industry: productivity challenges and trends

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

A decade of fragment-based drug design: strategic advances and lessons learned

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Structure-based drug design to augment hit discovery

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Initial sequencing and analysis of the human genome

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Virtual screening of chemical libraries

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Role of the development scientist in compound lead selection and optimization

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Recent development and application of virtual screening in drug discovery: an overview

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Drug-like properties and the causes of poor solubility and poor permeability

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Recent advances in computer-aided drug design

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Prediction of Caco-2 cell permeability using a combination of MO-calculation and neural network.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Inhibitors of HIV-1 protease: a major success of structure-assisted drug design

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Selective inhibition of factor inhibiting hypoxia-inducible factor

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

The prolyl hydroxylase oxygen-sensing pathway is cytoprotective and allows maintenance of mitochondrial membrane potential during metabolic inhibition

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2)

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Design and synthesis of a series of novel pyrazolopyridines as HIF-1alpha prolyl hydroxylase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Hypoxia-inducible factor prolyl hydroxylase 2 has a high affinity for ferrous iron and 2-oxoglutarate

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Characterization of a robust enzymatic assay for inhibitors of 2-oxoglutarate-dependent hydroxylases.

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Reactivation of hepatic EPO synthesis in mice after PHD loss

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Identification of novel potential HIF-prolyl hydroxylase inhibitors by in silico screening

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Can the pharmaceutical industry reduce attrition rates?

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

New era for drug discovery and development in renal disease

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Inhibition of prolyl hydroxylase domain-containing protein suppressed lipopolysaccharide-induced TNF-alpha expression

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Structure-guided design of substituted aza-benzimidazoles as potent hypoxia inducible factor-1α prolyl hydroxylase-2 inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Identification of the renal erythropoietin-producing cells using transgenic mice

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.796358

21 January 2018

Identifiers

10.1517/17460441.2013.796358

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38103912&oldid=1741829393"